Table 1 Univariate COX analysis and multivariate analysis of BHLHE40 in PAAD from TCGA datasets.
From: BHLHE40, a potential immune therapy target, regulated by FGD5-AS1/miR-15a-5p in pancreatic cancer
Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Pathologic T stage | 177 | Â | 0.045 | Â | Â |
 T1 and T2 | 31 | Reference |  | Reference |  |
 T3 | 143 | 2.056 (1.090–3.878) | 0.026 | 1.619 (0.581–4.513) | 0.357 |
 T4 | 3 | 1.091 (0.140–8.489) | 0.934 | 1.375 (0.141–13.425) | 0.784 |
Pathologic N stage | 174 | Â | 0.002 | Â | Â |
 N0 | 50 | Reference |  | Reference |  |
 N1 | 124 | 2.161 (1.287–3.627) | 0.004 | 1.719 (0.827–3.574) | 0.147 |
Pathologic M stage | 85 | Â | 0.713 | Â | Â |
 M0 | 80 | Reference |  |  |  |
 M1 | 5 | 0.773 (0.185–3.227) | 0.724 |  |  |
Pathologic stage | 176 | Â | 0.018 | Â | Â |
 Stage I | 21 | Reference |  | Reference |  |
 Stage II and stage III and stage IV | 155 | 2.309 (1.059–5.033) | 0.035 | 0.694 (0.165–2.918) | 0.618 |
Primary therapy outcome | 140 |  |  < 0.001 |  |  |
 PD | 50 | Reference |  | Reference |  |
 SD and PR and CR | 90 | 0.403 (0.255–0.637) |  < 0.001 | 0.530 (0.324–0.868) | 0.012 |
Residual tumor | 165 | Â | 0.028 | Â | Â |
 R0 | 107 | Reference |  | Reference |  |
 R1 and R2 | 58 | 1.650 (1.064–2.558) | 0.025 | 1.426 (0.863–2.356) | 0.166 |
BHLHE40 | 179 | Â | 0.006 | Â | Â |
 Low | 89 | Reference |  | Reference |  |
 High | 90 | 1.787 (1.177–2.712) | 0.006 | 1.287 (0.786–2.106) | 0.316 |
